WO2026033474 - DEUTERATED COMPOUNDS AND USES THEREOF
National phase entry is expected:
Publication Number
WO/2026/033474
Publication Date
12.02.2026
International Application No.
PCT/IB2025/058080
International Filing Date
07.08.2025
Title **
[English]
DEUTERATED COMPOUNDS AND USES THEREOF
[French]
COMPOSÉS DEUTÉRÉS ET LEURS UTILISATIONS
Applicants **
TAKEDA PHARMACEUTICAL COMPANY LIMITED
Inventors
LEIT DE MORADEI, Silvana M.
Priority Data
63/680,774
08.08.2024
US
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
EPO
* |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| Translation |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 4077 | |
| EPO | Filing, Examination, Granting | 33723 | |
| Japan | Filing, Examination, Granting | 3359 | |
| South Korea | Filing, Examination, Granting | 4399 | |
| USA | Filing, Examination, Granting | 18840 |
Total:
64,398
Contact Us
Abstract[English]
The present invention provides deuterium-enriched tyrosine-protein kinase 2 (TYK2) inhibitors, pharmaceutical compositions, and methods of using such deuterium-enriched tyrosine-protein kinase 2 (TYK2) inhibitors and pharmaceutical compositions to treat, prevent, or ameliorate a disease, disorder, or condition mediated by TYK2.[French]
La présente invention concerne des inhibiteurs de tyrosine-protéine kinase 2 enrichis en deutérium (TYK2), des compositions pharmaceutiques et des procédés d'utilisation de tels inhibiteurs de tyrosine-protéine kinase 2 enrichis en deutérium (TYK2) et des compositions pharmaceutiques pour traiter, prévenir ou améliorer une maladie, un trouble ou un état médié par TYK2.